Reneuron Share News (RENE)

Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials.The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun.The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year.Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards "further important clinical milestones" over the next 18 months."In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine," Hunt said.Reneuron announced in April that it would be appointing a new CEO in order to "manage the increasing breadth of the company's clinical, operational and commercial activities".The company said on Tuesday that the planned recruitment process for Hunt's replacement is "proceeding well" and should be concluded shortly.The stock was up 4.7% at 3.98p in early deals.BC